- Home
- NVCR
NVCR
NovoCure Limited
as 02-21-2025 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Upcoming Earnings Alert:
Get ready for potential market movements as NovoCure Limited NVCR prepares to release earnings report on 27 Feb 2025.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 2.3B | IPO Year: | 2015 |
| Target Price: | $33.40 | AVG Volume (30 days): | 700.2K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $34.13 | Next Earning Date: | 02-27-2025 |
| Revenue: | $577,738,000 | Revenue Growth: | 14.63% |
| Revenue Growth (this year): | 19.97% | Revenue Growth (next year): | 2.83% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | Jan 11 '25 | Sell | $26.81 | 2,160 | $57,906.14 | 31,437 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insider Monkey
23 days ago
Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’
MT Newswires
a month ago
NovoCure Opens New Global Headquarters in Switzerland
Business Wire
a month ago
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
Simply Wall St.
a month ago
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain
Business Wire
a month ago
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Business Wire
2 months ago
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
TipRanks
2 months ago
Novocure price target raised to $42 from $28 at Piper Sandler
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.